Clinical efficacy and prognosis of adjuvant radiotherapy after breast-conserving surgery for stage I—II breast cancer

Q. Zhong,Q. Rong,Yu Tang,Yong Yang,L. Long,J. Jin,Yueping Liu,Yong-wen Song,H. Fang,Bo Chen,S. Qi,Ning Li,Yuan Tang,Jianghu Zhang,N. Lu
DOI: https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2018.02.009
2018-02-15
Abstract:Objective To evaluate the clinical efficacy and analyze the prognostic factors of radiotherapy after breast-conserving surgery for stage Ⅰ—Ⅱ breast cancer patients. Methods Clinical efficacy of adjuvant radiotherapy in 1376 patients with stage Ⅰ and Ⅱ(T1-2N0-1M0/T3N0M0) breast cancer after undergoing unilateral breast-conserving surgery between 1999 and 2013 was retrospectively reviewed. Among them, 930 patients (67.6%) received radiotherapy combined with chemotherapy including 517 receiving radiotherapy followed by chemotherapy and 413 receiving chemotherapy followed by radiotherapy. In total, 1055 patients (76.7%) were treated with endocrine therapy. Eighty-six patients (39.6%) positive for HER-2 received targeted therapy. The overall survival (OS) and disease-free survival (DFS) rates were calculated using the Kaplan-Meier method. Univariate analysis was performed by Log-rank test and multivariate analysis was conducted by Cox regression method. Results The median follow-up time was 55 months. The quantity of patients receiving follow-up for ≥ 10 years was 90. The 5-and 10-year OS rates for all patients were 98.6% and 91.5%, and 94.6% and 82.8% for 5-and 10-year DFS rates. Mutivariate analysis revealed that age (P=0.016), T staging (P=0.006), N staging (P=0.004), lymphovascular invasion (P=0.038) and time interval between radiotherapy and surgery (P=0.048) were independent prognostic factors for DFS rate. Multivariate analysis demonstrated that N staging (P=0.044) and ER (P=0.026) were independent prognostic factors for DFS in the radiotherapy alone group. Conclusions The radiotherapy-based comprehensive treatment yields favorable clinical outcomes for stage Ⅰ—Ⅱ breast cancer patients after undergoing breast conserving surgery. The prognostic factors for DFS include age, T staging, N staging, lymphovascular invasion and the time interval between radiotherapy and breast-conserving surgery. In the radiotherapy alone group, DFS rate is associated with N staging and ER level. Key words: Breast neoplasm/radiotherapy; Breast neoplasm/chemotherapy; Prognosis
Medicine
What problem does this paper attempt to address?